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rePrevious studies have shown that patients with Takotsubo syndrome (TS) have supranormal nitric oxide
signaling, and post-mortem studies of TS heart samples revealed nitrosative stress. Therefore, we first showed
in a female rat model that isoproterenol induces TS-like echocardiographic changes, evidence of nitrosative
stress, and consequent activation of the energy-depleting enzyme poly(ADP-ribose) polymerase-1. We
subsequently showed that pre-treatment with an inhibitor of poly(ADP-ribose) polymerase-1 ameliorated
contractile abnormalities. These findings thus add to previous reports of aberrant b-adrenoceptor signaling
(coupled with nitric oxide synthase activation) to elucidate mechanisms of impaired cardiac function
in TS and point to potential methods of treatment. (J Am Coll Cardiol Basic Trans Science 2018;3:213–26)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T akotsubo syndrome (TS) reflectscatecholamine-induced globalmyocardial inflammation, which
predominantly affects the left ventricular
(LV) apex. Since its initial description byJapanese investigators (1), the phenomenon of TS has
aroused considerable interest among clinicians, as its
differentiation from acute myocardial infarction rep-
resents a diagnostic challenge (2,3). Even more
intriguing is the epidemiology of TS, with its predomi-
nant occurrence in aging women, episodes being
precipitated both by acute emotional or physical
stressors and the presence of neuropsychiatric disor-
ders (4,5). Furthermore, it was originally considered
that TS might be a relatively rare disorder, which is
not the case: approximately 10% of suspectedSEE PAGE 227ST-segment elevation myocardial infarction cases
in women aged >50 years are actually TS (6). Finally,
TS induces prolonged myocardial inflammation (7),
including patchy inflammatory infiltrate on myocar-
dial biopsy samples (8), with persistent LV dysfunction
(9), disordered cardiac energetics (10), and associated
impairment of quality of life for $3 months, with a
propensity toward recurrence (11).
To date, the only definitive progress that has been
made regarding the pathogenesis of TS is related to
the pivotal role of catecholamine release and its in-
teractions with the myocardium: there is extensive
evidence that TS can be induced by both endogenoush and Medical Research Council (Australia). Mr. Surikow, Dr. R
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contractility (with minimal myocardial necrosis) fol-
lowed by a prolonged phase of slowly resolving
intense and essentially global myocardial inflamma-
tion and associated edema. Among systemic markers
of myocardial inflammatory activation, substantial
release of B-type natriuretic peptide/N-terminal
pro–B-type natriuretic peptide in the absence of
pulmonary edema serves best to delineate the prog-
ress of attacks (13). However, the precise cause of this
inflammatory activation remains uncertain.
Studies in rodent models of TS have added sub-
stantially to the understanding of the impairment of
myocardial contractility and associated propensity
toward shock in the acute phases of the disorder.
Notably, 2 studies have suggested a pivotal role for
stimulation of b2-adrenoceptors, with an associated
shift from Gs- to Gi-based signal transduction, medi-
ating cardiodepressant (but also cardioprotective)
effects (14,15). However, the findings of these
investigations do not address the issue of the patho-
genesis of the myocardial inflammation that follows
the initial catecholamine exposure, nor has any
mechanism for inflammatory activation in TS been
suggested by other previous experiments.
We made a series of observations which suggest
that nitrosative stress may be critical to both inflam-
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215that patients with TS differ from age-matched female
control subjects with regard to 2 aspects of nitric
oxide (NO) signaling (16). Specifically, patients with
TS exhibited greater platelet responsiveness to the
antiaggregatory effects of NO. Furthermore, plasma
concentrations of asymmetric dimethylarginine, a
competitive inhibitor of NO generation, were signifi-
cantly lower in patients with TS than in control
subjects. If release and/or effects of NO are increased
in patients with TS, this result may be particularly
relevant under conditions of b2-adrenoceptor stimu-
lation, given that b2-adrenoceptors are coupled to
activation of nitric oxide synthase (NOS) (17).
Increased release of NO in the presence of the su-
peroxide (O2–) anion, which is also incrementally
produced by the actions of catecholamines on the
myocardium (18), potentially induces formation of
the peroxynitrite (ONOO–) anion. This action induces
associated redox stress, protein nitration (19), and
deoxyribonucleic acid damage, resulting in activation
of poly(ADP-ribose) polymerase (PARP)-1, which
among other effects, acts as an “energy sink” (20);
nicotinamide adenine dinucleotide is directly
depleted, leading to potential phosphocreatine
depletion, with associated inhibition of glycolysis (21).
Pilot immunohistological studies of LV myocar-
dium in patients dying early in the course of TS
indeed reported evidence of nitrosative stress:
increased myocardial content of the nitrosative stress
marker 3-nitrotyrosine (NT) and possibly increased
content of poly(ADP-ribose) (PAR), a downstream
product of PARP-1 activation (22), which represents a
potential mechanism of energetic impairment (20,23).
We therefore sought to evaluate the potential roles of
the generation of nitrosative stress, with the precursors
of ONOO– (O2– and NO) being incrementally generated
by increased b2-adrenoceptor stimulation (coupled to
NOS activation [17]) and by oxidative stress induced
primarily by catecholamine-triggered b1-adrenoceptor
stimulation and/or endothelial NOS “uncoupling,”
respectively; a rat model of TS was utilized.
We also sought to evaluate the impact of this pu-
tative cascade on expression of the pro-inflammatory
a-arrestin thioredoxin-interacting protein (TXNIP),
which might theoretically be increased either via
direct stimulation by ONOO– (24) and/or via with-
drawal of NO-mediated suppression (25). Given that
PARP-1 may activate nuclear factor kappa B (NFkB)
(26) via phosphorylation, myocardial content of
phosphorylated and total NFkB were also evaluated.
The nature of the cellular component of myocardial
inflammatory infiltrate in TS has been document only
minimally (8,27) thus far, and we also elected to
evaluate those changes. Furthermore, in a subsequentseries of experiments, the impact of PARP-1 inhibition
was evaluated to determine whether PARP-1 activa-
tion was mechanistically critical in this model.
METHODS
RAT MODEL. The goal of this study was to assess the
effects of isoproterenol on the myocardium of aging
female rats (n¼ 17; weight, 210 to 280 g) to most closely
mimic the demographic characteristics of TS in
humans. Preliminary experiments were conducted to
assess the impact of age and dose of isoproterenol on
tolerability; the results showed that in Sprague-Dawley
rats age >8 months, the mortality rates after injection
of isoproterenol were unacceptably high. Therefore,
the age of 4 to 5 months and a dose of 5 mg/kg were
eventually selected. Under these conditions, short-
term mortality (manifest generally between 0.5 and 2
h) was approximately 33%. Baseline echocardiography
was followed by a single intraperitoneal injection
of isoproterenol for treated rats, with follow-up echo-
cardiography performed 24 h later. Animals were then
killed, and the myocardium was harvested for immu-
nohistological and immunoblotting analyses. Control
rats (n ¼ 10) were killed after 24 h, without exposure to
isoproterenol, to provide immunohistochemical and
immunoblotting controls. This study was approved by
the relevant institutional ethics committees.
In a subsequent series of experiments, we evalu-
ated the impact of pre-treatment with the PARP-1
inhibitor 3-aminobenzamide (3AB) (50 mg/kg intra-
peritoneal injection) administered 30 min before
isoproterenol administration (ISO/3AB) (n ¼ 17).
Comparisons were made with rats treated with
isoproterenol alone (ISO) (n ¼ 17), blinded to treat-
ment group. Four rats were treated with 3AB alone.
Echocard iography . For baseline and 24-h analysis
of the effects of isoproterenol on LV structure and
function, rats were initially anesthetized with 2%
isoflurane, which was reduced to 0.5% during echo-
cardiography. Animals were placed on their backs on
a warming pad, their chest shaved and limb-leads
attached for electrocardiogram recording. A Vivid 7
ultrasound system with a 10S 2298589 sector array
probe (GE Vingmed Ultrasound AS, Horten, Norway),
at a frequency of 4.0 to 10.5 MHz, was used for the
acquisition of echocardiographic views. Views of the
parasternal long-axis, as well as parasternal short-
axis at the level of the base, mid, and apex, were
captured for assessment of the left ventricle.
LV wall thickness and fractional area shortening were
measured at end-diastole in the parasternal long-axis
view, by using two-dimensional echocardiography, at 3
pre-defined levels: 1) basal, measurements were
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216performed at 3 mm below the mitral annulus; 2) mid-
ventricle, measurements were recorded at the level of
the papillary muscle; and 3) apical, measurements were
performed 3 mm from the LV apex. Radial strain was
measured from the short-axis view at the level of the
apex with image depth set at approximately 2.0 to 2.5 cm
with a frame rate of 240 to 260 frames/s.
Echocardiographic images were transferred to an
EchoPAC PC workstation with Q analysis software
enabled (GE Vingmed Ultrasound AS). Experienced
investigators blinded to treatment status and phase of
treatment performed all analyses, with measurements
made in triplicate. Interobservation coefficient of
variability for the measurement of apical strain
was 13%.
Preparat ion of rat myocard ium. After 24-h follow-
up echocardiography, all rats were killed under anes-
thesia, and hearts were excised. Hearts were divided
into basal and apical LV sections, which were fixed in
4% formaldehyde for paraffin embedding and snap-
frozen in liquid nitrogen for immunoblotting analysis.
Immunohisto log ica l methods . Myocardial content
of the following was determined by immunohisto-
chemistry: 1) 3-NT, as a marker of nitrosative stress;
2) PAR, representing the principal product of PARP-1
action; 3) TXNIP, a pro-inflammatory a-arrestin;
4) CD68, as a marker of macrophage/monocyte infil-
tration; and 5) CD45, as a marker of leukocyte
infiltration.
In all cases, the methods utilized for these studies
were analogous, with variation only in the primary and
secondary antibodies and dilution used. Thus, the
sequence of quantitation involved the following steps.
First, 4-mm sections of tissue were cut and mounted
onto Menzel Superfrost Ultra Plus (Thermo Fisher
Scientific, Waltham, Massachusetts) slides, then
allowed to dry overnight in a 37C oven. Slides were
deparaffinized, followed by antigen retrieval in citrate
buffer at 100C. Slides were blocked for endogenous
peroxidase utilizing 3% hydrogen peroxide, followed
by protein blocking using DAKO serum-free protein
block (Agilent Technologies, Santa Clara, California).
The primary antibodies were as follows: 3-NT (Upstate
#06-284, Merck, Kenilworth, New Jersey), 1:500 dilu-
tion; PAR (Trevigen 4335-MC-100-AC, Bio-Techne,
Minneapolis, Minnesota), 1:100 dilution; CD68 (ED1,
Santa Cruz sc-59103, Dallas, Texas), 1:50 dilution and
CD45 (OX30, Santa Cruz sc-53047), 1:25 dilution; and
TXNIP (MBL Anti-TXNIP [VDUP1] mAb K0205-3, 1:500
dilution (Woburn, Massachusetts).
All primary antibodies were diluted in DAKO anti-
body diluent solution. Sections were left to incubate
overnight at 4C. The secondary antibody for 3-NT
was DAKO EnVisionþ System HRP Labelled PolymerAnti-Rabbit (k4003), 1:100 dilution; for PAR, CD68,
CD45, and TXNIP, Santa Cruz Biotechnology goat
anti-mouse IgG-HRP (sc-2005), 1:100 dilution.
Sections were left to incubate for 40 min at room
temperature. For visualization, liquid DAB þ Sub-
strate Chromogen System (DAKO, k3467) was applied
to each section, before being placed in distilled water
to finish the reaction. Slides were incubated in
hematoxylin for 10 s followed by 3 dips in Scott’s Tap
Water for counterstaining. Slides were then dehy-
drated, and coverslips were applied.
All slides are cleaned before being placed into the
NanoZoomer (Hamamatsu Photonics K.K., Shizuoka
Prefecture, Japan). Between 8 and 12 focus points
were individually selected for each section, depend-
ing on the size of the section. NanoZoomer creates
high-quality images of each section, allowing for ac-
curate analysis.
All analyses were performed by investigators
blinded as to rat treatment group. Reproducibility of
estimates was evaluated via determination of the
coefficient of variability. The images generated by
NanoZoomer were processed by using Aperio Image-
Scope version 12.3 (Leica Biosystems, Nussloch,
Germany), which generates a measure of the propor-
tion of the total slide occupied by the stain.
Immunoblott ing stud ies . Given the central impor-
tance of the 3-NT data, a subsidiary assay was per-
formed by using immunoblotting (data on 5 control
rates and 5 isoproterenol-treated rats, with blots in
triplicate). Apical and basal sections of rat hearts were
ground to a fine powder under liquid nitrogen and
homogenized in 1X lysis buffer that contained protease
and phosphatase inhibitor cocktails. The protein con-
centrations of supernatant were quantified in tripli-
cate by using the DC Protein Assay (Bio-Rad
Laboratories, Hercules, California) based on modifi-
cation of the Lowry method and prepared in Laemmli
sample buffer for separation at 30 mg protein/sample.
Proteins were separated by using a 7.6% sodium
dodecyl sulfate polyacrylamide gel electrophoresis
and transferred onto a nitrocellulose membrane
(Sigma). Blots were blockedwith 5%nonfatmilk in Tris
Buffered Saline, 0.01% Tween, at room temperature
for 2 h and then probed overnight at 4

C using primary
monoclonal antibodies (3-NT, Abcam, Cambridge,
United Kingdom; ab61392, 1:4,000 dilution). The same
blot was washed and re-probed for b-actin (Abcam,
ab8226, 1:5,000 dilution for 3-NT) to determine equal
sample to loading and then incubatedwith a secondary
HRP-conjugated antibody (3-NT, Santa Cruz Biotech-
nology; anti-mouse 1:5,000 dilution). The bands were
visualized by using ImageQuant LAS 4000 (GE
Healthcare Life Sciences). Band intensities were
TABLE 1 Echocardiographic Parameters for Isoproterenol Alone
Baseline 24 h p Value
Heart rate, beats/min 336.4  6.7 379.8  8.1 0.0003
Apical wall thickness, mm 15.9  0.4 19.5  0.5 <0.0001
Apical strain rate, % 40.1  1.6 24.7  1.5 <0.0001
Apical fractional area
shortening, %
50.0  2.2 38.4  2.5 0.0016
Ejection fraction, % 86.3  1.0 82.0  1.5 0.0075
Values are mean  SEM. Echocardiographic changes associated with intraperito-
neal administration of isoproterenol (5 mg/kg, n ¼ 17). The comparison is between
pre-treatment status and 24 h post-isoproterenol.
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217quantified by using Multi-Gauge Software. Effects on
expression of 2 bands of 3-NT relative to b-actin were
quantified for all experiments.
For subsequent experiments evaluating pre-
treatment with 3AB, immunoblotting was also
performed to compare expression of PARP-1 and
its product PAR in hearts 24 h post-ISO (n ¼ 10) or ISO/
3AB (n ¼ 10) treatment. The methods were as for 3-NT
(detailed above) but utilizing the primary antibodies
PARP (Cell Signaling Technologies, Danvers, Massa-
chusetts; #9542: 1:1,000 dilution) and PAR (Trevigen;
#4335-MC-100-AC: 1:800 dilution). The ratio of PAR
generation to PARP-1 expression was used as a
measure of PARP-1 activity.
Methods for NFkB were analogous to 3-NT and PARP/
PAR, although with primary antibody for NFkB (Phos-
phorylated NFkB, Cell Signaling Technology; #3033
1:2,000; Total NFkB, Cell Signaling Technology, #8242
1:1,000). A dilution of 1:2,000 for b-actin was used, with
secondary antibody at 1:5,000 (Santa Cruz Biotech-
nology, anti-rabbit). The ratio of phosphorylated NFkB
to total NFkB was used as a measure of NFkB activation.
STATISTICAL ANALYSIS. All statistical analyses were
performed by using GraphPad Prism 7.02 (GraphPad
Software, La Jolla, California). Echocardiographic pa-
rameters were assessed via paired comparison of
baseline and 24-h echocardiograms, with evaluation
being performed while blinded as to experimental
sequence. Comparisons of parameters were performed
by using paired Student’s t tests for normally distrib-
uted parameters.
Evaluation of differences in content and regional
distribution (apical vs. basal myocardium) of 3-NT,
TXNIP, and PAR was performed by using 2-way
analysis of variance (ANOVA).
For evaluation in subsequent experiments of the
impact of 3AB on ISO-induced changes, all statistical
comparisons (unpaired) were between subsequently
treated ISO rats and ISO/3AB–treated rats. Data
involving effects of intervention (ISO or 3AB,
respectively) on the difference between parameters at
baseline and 24 h were normally distributed and were
analyzed by using 2-way ANOVA. All data are
expressed as mean  SEM unless otherwise stated.
RESULTS
EFFECTS OF ISO. Echocard iograph ic findings . After
injection of isoproterenol (5 mg/kg intraperitoneally),
11 of 28 rats died suddenly within 2 h; data for the
surviving 17 rats were analyzed. Overall appearances
of the left ventricle included a variable degree of
apical hypokinesis. Major echocardiographic changes
induced by isoproterenol are depicted in Table 1.Specifically, there was approximately a 15% increase
in heart rate, apical LV wall thickness increased
(consistent with the presence of myocardial edema),
and apical strain rate decreased markedly (Figure 1),
with a smaller, yet significant, decrease in apical
fractional shortening and ejection fraction.
Histology/immunohistochemistry. The LVmyocardium in
isoproterenol-treated rats was infiltrated mainly with
macrophages/monocytes (CD68þ) rather than leuko-
cytes (CD45þ), consistent with activation of a cellular
component of an inflammatory process (Figure 2).
3-NT accumulated significantly, especially in the
apical myocardium (p ¼ 0.0024) (Figures 3A, 4A, and 4B).
There was approximately a 4-fold increase in 3-NT
content (from 5.7  0.7% to 21.2  6.9%) of the apical
myocardium of control rats compared with
isoproterenol-treated animals.
PAR content increased significantly (p ¼ 0.014)
(Figures 3B, 4E, and 4F), although less markedly than
with 3-NT. For example, apical PAR content was 1.9 
0.1% in control rats and 2.9  0.2% in isoproterenol-
treated animals.
The TXNIP content of myocardium in isoproterenol-
treated rats increased approximately 2.5-fold relative to
control rats (Figures 3C, 4C, and 4D), with a significant
apex-to-base gradient. Although this increase was
not dissimilar to that seen with 3-NT, there was no sig-
nificant correlation between 3-NT and TXNIP content.
Immunoblott ing . 3-NT immunoblotting consis-
tently generated 2 bands of molecular weight (47 and
70 kDa, respectively) (Figure 5), as shown in previous
studies (28). Changes were quantitated regarding each
individual band, rather than averaging data. These
revealed (via 2-way ANOVA) a significant increase in
the 47-kDa band (p ¼ 0.003) and a borderline increase
in the 70-kDa band (p ¼ 0.05) with isoproterenol
treatment without obvious regional variability.
COMPARISONS BETWEEN ISO AND ISO/3AB.
Echocardiographic/clinical findings. Mortality with ISO/
3AB was approximately 32%, which is not signifi-
cantly different from ISO alone. Data are presented on
FIGURE 1 Functional Effects of ISO Alone
Echocardiographic strain data derived from apical myocardial motion in (A) pre-treated state and (B) 24-h post-injection of isoproterenol (ISO). Post-ISO
analysis showed marked impairment of apical radial strain. Ant ¼ anterior; AntSept ¼ anteroseptal; AVC ¼ aortic valve closure; Inf ¼ inferior; Lat ¼ lateral;
Post ¼ posterior; SAX-AP ¼ short axis-apex; Sept ¼ septal; SR ¼ strain rate.
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FIGURE 2 Effects of ISO on Inflammatory Markers
Leukocyte infiltration, as measured by CD45, is shown in (A) control rat myocardium and (B) isoproterenol (ISO)-treated myocardium, with (C) summary data.
Macrophage infiltration, measured with CD68 expression, is shown in (D) control rat myocardium and (E) ISO-treated myocardium, with (F) summary data. Five
sections from each group were analyzed (20 sections in total); black/dark brown represents positive staining. *p < 0.05.
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219the 17 surviving rats. Apical radial strain and frac-
tional shortening remained preserved in the ISO/3AB
group at 24 h compared with the ISO alone group
(time-treatment interaction values, p ¼ 0.0004 and
p ¼ 0.037, respectively) (Table 2, Figure 6). Other
echocardiographic measurements, such as apical wall
thickness or heart rate, were not significantly
different between the ISO alone and ISO/3AB groups.
3AB alone induced no changes in wall motion (data
not shown).FIGURE 3 Immunohistochemical Results for ISO Alone (Summative
Effects of isoproterenol (ISO) on regional accumulation of 3-nitrotyrosine
myocardium. (A) 3-NT mean values at apex and base. Two-way analysis o
mean values at apex and base. Two-way ANOVA: ISO, p < 0.0001; apex
ANOVA: ISO, p < 0.0001; apex/base, p ¼ 0.002; and interaction, p ¼ 0Histo logy/ immunohistochemistry . CD68 content
tended to decrease with ISO/3AB compared with ISO
alone (mean 10.0  3.3 to 7.2  3.1), but this finding
did not reach statistical significance.
3-NT content was not significantly different be-
tween treatment groups at 24 h (treatment p > 0.05)
(Figures 7A, 8A, and 8B).
PAR content was increased in the ISO/3AB group
compared with the ISO alone group (treatment
p ¼ 0.0001) (Figures 7B, 8E, and 8F).Data)
(3-NT), poly(ADP-ribose) (PAR), and thioredoxin-interacting protein (TXNIP) in left ventricular
f variance (ANOVA): ISO, p ¼ 0.002; apex/base, p ¼ 0.03; and interaction, p ¼ 0.23. (B) PAR
/base, p ¼ 0.01; and interaction, p ¼ 0.93. (C) TXNIP mean values at apex and base. Two-way
.57. Two slides were analyzed per rat (apex and base); values are mean  SEM. *p < 0.05.
FIGURE 4 Immunohistochemical Effects of ISO Alone (Representative Images)
Effects of ISO on 3-NT, TXNIP, and PAR expression in the myocardium. The accumulation of 3-NT is shown in (A) control rat myocardium and
(B) ISO-treated myocardium. TXNIP accumulation is shown in (C) control rat myocardium and (D) ISO-treated myocardium. PAR accumulation
is shown in (E) control rat myocardium and (F) ISO-treated myocardium. Abbreviations as in Figure 3.
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myocardium of ISO/3AB–treated rats compared with
rats receiving ISO alone (treatment p < 0.001)
(Figures 7C, 8C, and 8D).
Immunoblott ing . PARP-1 immunoblotting (116-kD
fragment) revealed that apical PARP-1 expression
did not significantly differ at 24 h between ISO-
treated rats and ISO/3AB–treated rats (6.9  2.7 vs.
2.1  0.8; ANOVA, p ¼ 0.16).
PAR formation also did not change significantly
(37.9  10.7 for ISO and 32.8  8 for ISO/3AB;
p ¼ 0.90).
Phosphorylated:total NFkB ratios were not signifi-
cantly different between groups after performing a
2-way ANOVA with Dunnett’s test for multiple
comparisons (p ¼ 0.43).
DISCUSSION
The current experiments were conducted to
evaluate the possible occurrence, and potentialpathophysiological impact, of nitrosative stress in an
animal model of TS. We showed, in female rats
injected with isoproterenol, that precipitation of TS-
like echocardiographic changes (29) was associated
with intramyocardial accumulation of 3-NT, a con-
ventional marker of nitrosative stress (19), and of
PAR, a product of PARP-1 activation and thus a
marker and mediator of myocardial energetic
impairment (30). Myocardial TXNIP content was also
significantly increased after ISO administration,
consistent with increased stimuli for its expression,
such as withdrawal of NO effect (25) and/or disruption
of laminar flow and associated shear stress (31); this
process known to be precipitated by glycocalyx
shedding, a recently delineated component of TS (32).
We also reported the presence of inflammatory infil-
trate, with a substantial increase in CD68þ cells,
representing predominantly macrophage/monocyte
infiltration. Furthermore, as noted on echocardiog-
raphy, LV wall thickness increased significantly with
ISO. In a sequential series of experiments, the PARP-1
inhibitor 3AB substantially limited the severity of
FIGURE 5 Immunoblotting Results for 3-NT
These demonstrate a significant increase in the 47-kDa band
(p ¼ 0.003) and a borderline increase in the 70-kDa band
(p ¼ 0.05) (2-way ANOVA) with ISO treatment without
statistically significant regional variability between apex and
base. Five control rats were compared with 5 ISO-treated
rats, with blots completed in triplicate. Western blots;
CA ¼ control apex; CB ¼ control base; IA ¼ ISO apex; IB ¼ ISO
base; other abbreviations as in Figure 3.
TABLE 2 Echocardiographic Parameters for ISO Versus ISO/3AB
ISO ISO/3AB
p ValueBaseline 24 h Baseline 24 h
Heart rate, beats/min 336.4  6.7 379.8  8.1 347.5  6.4 374.1  5.4 0.21
Apical wall thickness, mm 15.9  0.4 19.5  0.5 15.4  0.2 18.5  0.4 0.64
Apical strain rate, % 40.1  1.6 24.7  1.5 42.7  0.9 37.1  1.1 0.0004
Apical fractional area
shortening, %
50.0  2.2 38.4  2.5 46.4  1.2 41.2  1.2 0.001
Ejection fraction, % 86.3  1.0 82.0  1.5 83.6  1.1 82.0  1.1 0.25
Values are mean  SEM. Echocardiographic changes associated with intraperitoneal administration of isopro-
terenol alone (ISO: 5 mg/kg, n ¼ 17) and isoproterenol þ 3-aminobenzamide (ISO/3AB: 50 mg/kg, n ¼ 17).
Analysis is via 2-way analysis of variance, and p values are for time/treatment interaction.
FIGURE 6 Functional Effects of ISO/3AB
Changes in left ventricular apical radial strain over 24 h after
ISO (solid line) or ISO/3-aminobenzamide (3AB) (dotted line).
Two-way ANOVA: interaction, p ¼ 0.0004; treatment,
p < 0.0001; and time, p < 0.0001. Values are mean  SEM.
*p < 0.05. Abbreviations as in Figure 3.
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relative to ISO alone.
These findings are therefore consistent with four
observations from our clinical investigations of TS.
First, patients with TS usually have increased tissue
responsiveness to NO and decreased concentrations
of asymmetric dimethylarginine. These fluctuations
facilitate ONOO– generation (19). Second, pilot studies
in patients dying of TS also revealed increased
myocardial 3-NT content (22). Third, myocardial
energetic impairment persists for at least 4 months
after acute attacks of TS (10). Finally, glycocalyx
shedding occurs in the acute stages of TS (32), which
increases cellular permeability and may contribute to
the prolonged and characteristic accentuation of
myocardial edema (33) in this condition. A schematic
representation of these findings is provided in
Figure 9.
The current findings are also consistent with the
fact that myocardial b2-adrenoceptors are linked toNOS (34); b2-adrenoceptor stimulation would be
expected to increase NO release in this manner. It has
previously been shown that b2-adrenoceptor density
relative to that of b1-adrenoceptors is greatest in the
LV apical myocardium (15). In the rat ventricle,
b-adrenoceptor–stimulated release of NO increases
with senescence (35). Indeed, in the current experi-
ments, even in control hearts, there was a trend for
apical 3-NT content to exceed basal. In terms of the
propensity for increased NO generation to induce
nitrosative stress in the presence of oxidative stress,
this factor has been previously shown in models of
both central neuronal injury (36) and anthracycline-
induced cardiac injury (37). Intriguingly, Zhang et al.
(38) described the protective effects of hydrogen
FIGURE 8 Immunohistochemical Effects of ISO Versus ISO/3AB (Representative Images)
Effects of ISO on 3-NT, TXNIP, and PAR expression in the myocardium, in the presence of ISO and in the absence of the poly(ADP-ribose)
polymerase-1 inhibitor 3AB (ISO/3AB). 3-NT accumulation is shown in (A) ISO-treated myocardium and (B) ISO/3AB-treated myocardium.
TXNIP accumulation is shown in (C) ISO-treated myocardium and (D) ISO/3AB-treated myocardium. PAR accumulation is shown in (E)
ISO-treated myocardium and (F) ISO/3AB-treated myocardium. Abbreviations as in Figures 3 and 6.
FIGURE 7 Immunohistochemical Results for ISO Versus ISO/3AB (Summative Data)
Effects of ISO on regional accumulation of 3-NT, PAR, and TXNIP in left ventricular myocardium with 3AB (ISO/3AB) and without (ISO). (A) 3-NT, showing mean values
at apex and base. Two-way ANOVA: 3AB, p ¼ 0.44; apex/base, p ¼ 0.17; and interaction, p ¼ 0.18. (B) PAR mean values at apex and base. Two-way ANOVA: 3AB,
p ¼ 0.0001; apex/base, p ¼ 0.0043; and interaction, p ¼ 0.86. (C) TXNIP mean values at apex and base. Two-way ANOVA: 3AB, p < 0.0001; apex/base, p ¼ 0.57; and
interaction, p ¼ 0.26. Two slides were analyzed per rat (apex and base); values are mean  SEM. *p < 0.05. Abbreviations as in Figures 3 and 6.
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FIGURE 9 Proposed TS Signal Transduction Cascade
ISO injection results in b-adrenoceptor activation, leading to activation of coupled endothelial nitric oxide synthase (eNOS) receptors and to
mitochondrial reactive oxygen species release. With increased superoxide (O2
–) and nitric oxide (NO) production, there is formation of
peroxynitrite (ONOO–), leading to protein nitration, myocardial inflammation, and poly(ADP-ribose) polymerase-1 (PARP-1) activation,
resulting in energetic impairment as well as PAR production. Inflammatory activation of glycocalyx shedding contributes to the development
of edema and to increased expression of TXNIP. ATP ¼ adenosine triphosphate; BNP ¼ B-type natriuretic peptide; DNA ¼ deoxyribonucleic
acid; iNOS ¼ inducible nitric oxide synthase; NADþ ¼ nicotinamide adenine dinucleotide; other abbreviations as in Figure 3.
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223sulfide in isoproterenol-treated rats, a benefit
apparently resulting from reversal of catecholamine-
induced reactive oxygen species generation.
However, ONOO–-related markers were not assessed
in this study.
The finding that the cellular myocardial infiltrate
in this model consists primarily of macrophages/
monocytes raises issues, including the basis for
their presence within the myocardium and their
potential contribution to myocardial cell damage. A
previous study in an atherosclerotic mouse model(39) found that macrophage/monocyte infiltration
may result primarily from glycocalyx shedding,
which itself is engendered largely by matrix metal-
loproteinase activation. Therefore, one potential
means of evaluating this cascade of events
(Figure 9) in terms of the impact on myocardial
function would be to evaluate the effects of matrix
metalloproteinase inhibitors (e.g., low-dose doxy-
cycline) (40).
In view of the findings in the rats treated with
isoproterenol alone, the question inevitably arises: is
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development of the TS-like LV systolic dysfunction in
this model?
We chose to address, in a subsequent series of
rats, the hypothesis that the PARP-1 inhibitor 3AB
might attenuate the contractile abnormalities seen
with isoproterenol alone. In the event, 3AB did
indeed significantly and markedly attenuate apical
systolic dysfunction (Figure 6, Table 2). As expected
from our overall construct (Figure 9), this finding
was associated with no change in myocardial 3-NT
content. In terms of the role of PARP-1 activity
and formation of PAR, it must first be stated that in
most models of acute cellular injury, PARP-1 acti-
vation is relatively transient, peaking within 4 h
(41,42). Thus, the cardioprotective impact of 3AB
would be exerted primarily during these first few
hours. The observed increase in PAR content at 24 h
(on immunohistochemical evaluation) suggests
restoration of PAR formation after washout of 3AB.
Indeed, Zhao et al. (43) have shown that in an acute
myocardial infarction model, PARP protein expres-
sion level is increased for at least 8 weeks’ post-
administration of 3AB in association with acute
infarction. From our immunoblotting data, it ap-
pears that there is little or no residual PARP-1 in-
hibition after 24 h. Furthermore, Cieslar-Pobuda
et al. (41) have also documented evidence of pre-
cipitation of “rebound” oxidative stress 12 to 48 h
post–pulse therapy with PARP-1 inhibitors. Taken
together, these data suggest that reactivation of
PARP-1 occurs under these circumstances, without
limiting the overall utility of initial therapy.
The current results therefore represent the most
definitive evidence to date of a central role for
nitrosative stress in a model of TS. However, it re-
mains to be determined in the clinical setting to what
extent PARP-1 activation post–b2-adrenoceptor stim-
ulation contributes to the prolonged energetic
impairment that has recently been demonstrated
clinically in TS (10). For example, it is theoretically
possible that increased TXNIP content may have
contributed to energetic impairment as well as to
overall inflammatory activation (31).
Activation of PARP-1, apart from its role in
deoxyribonucleic acid repair, also functions as an
“energetic sink,” depleting adenosine triphosphate
(20) and inhibiting glycolysis (21) during the pro-
duction of PAR. If this effect is central to the
impairment of myocardial contractility, it would be
expected that inhibition of either the ONOO– effect
(44) or of PARP-1 (23) would ameliorate TS. Bothexperimentally and clinically based investigations
to evaluate this possibility seem appropriate under
the current circumstances. In this regard, the
finding on meta-analysis that utilization of
angiotensin-converting enzyme inhibitors (which
limit PARP-1 activation [45]) may limit recurrence of
TS (46) is consistent with a known effect on nitro-
sative stress (47).
STUDY LIMITATIONS. There are several limitations to
the current study, beginning with those inherent in an
animal model. We investigated only single doses of
isoproterenol and 3AB, with a single post-intervention
time point (while both earlier and later evaluation
might well have been useful), and therefore needed
only a relatively small sample size. Furthermore,
although we detected nitrosative stress, we have not
yet determined whether the observed negative
inotropic changes might also partially reflect
ONOO–-mediated effects, independent of PARP-1
activation (44). We have also not determined to what
extent the observed contractile changes in this model
are initiated by b-adrenoceptor–triggered NOS
activation.
It is important to recognize that 3AB limited, but
did not totally abolish, the negative inotropic effects
of isoproterenol. Hence, it is possible that other
biochemical mediators may contribute to these
changes. For example, Willis et al. (48) used a rat
model similar to that in the current study but evalu-
ated residual impairment of contractility after 2
weeks. At that stage, both impaired oxidative meta-
bolism and calcium mishandling in both systole and
diastole were shown to underlie contractile
impairment.
The extent of myocardial edema associated with
the acute increase in LV wall thickness was not
determined, and therefore it is uncertain to what
extent this finding might have been due to swelling of
inflamed myocardial cells. Other studies have re-
ported, for example, increased cardiomyocyte diam-
eter (49) and/or increased cardiac weight (50) without
specifically investigating the potential role of
increased tissue fluid load; further clarification of this
issue is therefore a priority. In terms of the potential
duration of inflammatory changes post-isoproterenol
administration, a number of studies (50,51) have
evaluated the impact of prolonged isoproterenol
administration in the rat model, documenting a
plateau effect early regarding negative inotropy
and a diminution of presumptive inflammation/
edema after day 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Although it is
now clear that TS is a relatively common cause of disability and
death, especially in aging women, there is no current consensus
as to how, in susceptible hearts, catecholamine exposure induces
inflammatory activation within the myocardium, with systolic
dysfunction and associated energetic impairment. Despite its
substantial long-term mortality rate, TS has no established
treatment. However, the presence of nitrosative stress, previ-
ously reported in post-mortem heart samples, represents a
theoretical basis for therapeutic intervention.
TRANSLATIONAL OUTLOOK: We found that in hearts of
female rats, exposure to b2-adrenoceptor stimulation induces
TS-like ventricular dysfunction, nitrosative stress, and down-
stream activation of the “energetic sink” enzyme PARP-1.
These findings raise a number of potential therapeutic options
for both acute management and long-term treatment post-TS,
including inhibition of NOS, “scavenging” of ONOO–, PARP-1
inhibition, and use of angiotensin-converting enzyme
inhibitors.
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225CONCLUSIONS
Until recently, it might have been considered that TS
was relatively rare and generally benign; the lack of
an effective treatment was therefore of little impor-
tance. With greater understanding of the natural
history of this disorder (33,52), and of the role of
nitrosative stress in the pathogenesis of TS (Figure 9),
it has become necessary to develop appropriate stra-
tegies to treat the myocardial inflammatory activation
that drives the clinical features of TS.
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